We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.85%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$16.7M
(-5.5%)
Cap. Flow
-$5.1M
Cap. Flow
% of AUM
-1.78%
Top 10 Holdings %
Top 10 Hldgs %
46.84%
Holding
97
New
24
Increased
16
Reduced
16
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KYNB
Kyntra Bio
KYNB
|
+$16.3M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$13M |
| 3 |
Biogen
BIIB
|
+$11.9M |
| 4 |
Establishment Labs
ESTA
|
+$6.8M |
| 5 |
Kura Oncology
KURA
|
+$6.54M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$16.8M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$16.1M |
| 3 |
Merck
MRK
|
+$12.8M |
| 4 |
Viking Therapeutics
VKTX
|
+$6.75M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$6.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Madrigal Pharmaceuticals
MDGL
$12.8B
| $21.4M | 7.46% |
92,500
-500
| -0.5% | -$135K |
|
|
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $17.5M | 6.11% |
550,000
+170,000
| +45% | +$5.22M |
|
|
3
Establishment Labs
ESTA
$2.72B
| $14.5M | 5.07% |
211,608
+98,384
| +87% | +$6.8M |
|
|
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $12.3M | 4.31% |
321,017
-655,004
| -67% | -$16.8M |
|
|
5
CALL
Madrigal Pharmaceuticals
MDGL
$12.8B
| $12.3M | 4.28% |
+53,100
| New | +$14.4M |
|
|
6
Teva Pharmaceuticals
TEVA
$37.3B
| $12M | 4.21% |
+1,600,000
| New | +$13M |
|
|
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $11.6M | 4.04% |
201,887
+66,024
| +49% | +$3.45M |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $11.5M | 4.02% |
1,050,118
-33,000
| -3% | -$307K |
|
|
9
Biogen
BIIB
$30.4B
| $11.4M | 3.98% |
+40,000
| New | +$11.9M |
|
|
10
Kura Oncology
KURA
$964M
| $9.63M | 3.36% |
910,317
+553,030
| +155% | +$6.54M |
|
|
VRNA
11
DELISTED
Verona Pharma
VRNA
| $9.46M | 3.31% |
447,667
-5,154
| -1% | -$110K |
|
|
ACLX
12
DELISTED
Arcellx
ACLX
| $7.15M | 2.5% |
226,275
+23,441
| +12% | +$896K |
|
13
Prothena Corp
PRTA
$453M
| $6.83M | 2.38% |
+100,000
| New | +$6.45M |
|
14
PUT
BridgeBio Pharma
BBIO
$15.9B
| $6.47M | 2.26% |
376,000
-13,800
| -4% | -$208K |
|
|
15
PUT
Viking Therapeutics
VKTX
$4.31B
| $5.67M | 1.98% |
350,000
+256,100
| +273% | +$5.37M |
|
|
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
| $5.58M | 1.95% |
900,723
+216,596
| +32% | +$1.03M |
|
|
ATXS
17
DELISTED
Astria Therapeutics
ATXS
| $5.42M | 1.89% |
650,875
+121,506
| +23% | +$1.4M |
|
18
Ascendis Pharma A/S
ASND
$17.1B
| $5.16M | 1.8% |
57,760
+17,760
| +44% | +$1.55M |
|
19
Immunovant
IMVT
$8.27B
| $4.93M | 1.72% |
+260,000
| New | +$4.85M |
|
|
20
Viking Therapeutics
VKTX
$4.31B
| $4.86M | 1.7% |
300,000
-322,249
| -52% | -$6.75M |
|
21
AstraZeneca
AZN
$262B
| $4.29M | 1.5% |
30,000
| – | – |
|
|
INZY
22
DELISTED
Inozyme Pharma
INZY
| $4.19M | 1.46% |
751,796
| – | – |
|
23
Cytokinetics
CYTK
$10.9B
| $4.08M | 1.43% |
125,148
-96,315
| -43% | -$3.56M |
|
|
AUTL
24
Autolus Therapeutics
AUTL
$383M
| $3.78M | 1.32% |
+1,589,017
| New | +$3.77M |
|
25
Immatics
IMTX
$1.31B
| $3.46M | 1.21% |
+300,000
| New | +$2.8M |
|
Similar funds
FM
1SB
HCL
OCM
MWA
AF
NFG
HC
Affinity Asset Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, Affinity Asset Advisors held 97 positions worth $286M, down 5.5% from $303M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Affinity Asset Advisors's Q2 2023 filing shows 24 new, 16 increased, 16 reduced and 27 closed positions. Its largest new stake was Kyntra Bio: 39,332 shares worth $2.65M. The largest sale was Chinook Therapeutics, Inc. Common Stock, an estimated $16.8M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier.
- Affinity Asset Advisors's largest Q2 2023 buy was Kyntra Bio: 39,332 shares worth $2.65M.
- Affinity Asset Advisors added most to Establishment Labs in Q2 2023, an estimated $6.8M increase.
- Affinity Asset Advisors's biggest Q2 2023 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $16.8M.
- Affinity Asset Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
- Affinity Asset Advisors's ten largest holdings make up 47% of its $286M portfolio in Q2 2023.
- Affinity Asset Advisors opened 24 new positions and closed 27 in Q2 2023.
- Affinity Asset Advisors's portfolio value fell 5.5% quarter-over-quarter to $286M.
Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.